|
WO2021053678A1
|
|
Tumor environment specific expression of effector genes
|
|
WO2021033186A1
|
|
Compositions for inoculating aquatic animals
|
|
WO2021001834A1
|
|
Bacterial populations for desirable traits in ruminating animals
|
|
WO2020178816A1
|
|
Kits, compositions and methods for evaluating immune system status
|
|
US2020115348A1
|
|
Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction
|
|
IL267744D0
|
|
Labelling molecules and methods of use thereof
|
|
AU2019221324A1
|
|
Tumor environment-specific expression of chimeric antigen receptors
|
|
WO2019021289A1
|
|
Smac/diablo inhibitors useful for treating cancer
|
|
EP3630293A1
|
|
Biomarkers for diagnosis of lung cancer
|
|
WO2018173062A1
|
|
Angiopoietin 2-based polypeptide inhibitors and methods of use thereof
|
|
EP3582800A1
|
|
Peptide kinase inhibitors and methods of use thereof
|
|
WO2018116307A1
|
|
Methods for treating diabetes using vdac1 inhibitors
|
|
AU2017378451A1
|
|
Anti-PCNA monoclonal antibodies and use thereof
|
|
WO2018087757A1
|
|
Matrix metalloproteinase inhibitors and methods of use thereof
|
|
CA3039774A1
|
|
Non-cytotoxic modified cells and use thereof
|
|
US2018078548A1
|
|
Methods for treating central nervous system disorders using VDAC inhibitors
|
|
IL254361D0
|
|
Compositions for inhibition of the methyltransferase setd6
|
|
US2019255150A1
|
|
Fusion proteins with extended serum half life
|
|
IL252874D0
|
|
Monomeric and heterodimeric antagonists of mmp-14/2 and avb3 integrin
|
|
US2020270701A1
|
|
Biomarkers of chronic lymphocytic leukemia and use thereof
|
